
Maria Lucia Gomes Ferraz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1913051/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cholestatic pruritus: a knowledge update. Anais Brasileiros De Dermatologia, 2022, , .	0.5	6
2	HEPATIC ALTERATIONS IN KIDNEY TRANSPLANT RECIPIENTS FROM THE LARGEST KIDNEY TRANSPLANT CENTER IN BRAZIL. Arquivos De Gastroenterologia, 2022, 59, 65-70.	0.3	2
3	Performance of rapid test for antibodies to hepatitis C virus (anti-HCV) in hemodialysis patients and kidney transplant recipients. International Journal of Artificial Organs, 2022, 45, 680-684.	0.7	Ο
4	Evaluation of a strategy for identification of hepatitis C virus carriers in outpatient and emergency units: contribution to the microelimination of hepatitis C in Brazil. Brazilian Journal of Infectious Diseases, 2021, 25, 101546.	0.3	2
5	Selective decrease in complement C2 hemolytic activity is a sensitive marker for cryoglobulinemia and active disease in hepatitis C patients. Digestive and Liver Disease, 2021, 53, 860-865.	0.4	2
6	Six-minute walking test performance is associated with survival in cirrhotic patients. World Journal of Hepatology, 2021, 13, 1791-1801.	0.8	5
7	Autonomic dysfunction is common in liver cirrhosis and is associated with cardiac dysfunction and mortality: prospective observational study. Sao Paulo Medical Journal, 2021, , .	0.4	0
8	Brazilian Society of Hepatology and Brazilian Society of Infectious Diseases Guidelines for the Diagnosis and Treatment of Hepatitis B. Brazilian Journal of Infectious Diseases, 2020, 24, 434-451.	0.3	8
9	Iron Overload in Renal Transplant Patients: The Role of Hepcidin and Erythropoietin. Transplantation Proceedings, 2020, 52, 169-174.	0.3	6
10	Observational Study Evaluating the Outcome of Cirrhotic Hepatitis C Patients Submitted to Renal Transplantation. Transplantation Proceedings, 2020, 52, 89-96.	0.3	1
11	Plasma Lipidomic Fingerprinting to Distinguish among Hepatitis C-related Hepatocellular Carcinoma, Liver Cirrhosis, and Chronic Hepatitis C using MALDI-TOF Mass Spectrometry: a Pilot Study. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 43-49.	0.5	8
12	HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR. Arquivos De Gastroenterologia, 2020, 57, 45-49.	0.3	8
13	Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach. Brazilian Journal of Infectious Diseases, 2019, 23, 182-190.	0.3	37
14	How are HCV-infected patients being identified in Brazil: a multicenter study. Brazilian Journal of Infectious Diseases, 2019, 23, 34-39.	0.3	4
15	Hepatitis C in Hemodialysis Units: diagnosis and therapeutic approach. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2019, 41, 539-549.	0.4	7
16	Socioeconomic profile and degree of satisfaction of patients attending Gastroenterology Outpatient Clinics of a University Institution. Revista Da Escola De Enfermagem Da U S P, 2019, 53, e03436.	0.3	0
17	Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus. Infection and Drug Resistance, 2018, Volume 11, 1993-2000.	1.1	12
18	Latent Class Analysis of Noninvasive Methods and Liver Biopsy in Chronic Hepatitis C: An Approach without a Gold Standard. BioMed Research International, 2017, 2017, 1-8.	0.9	5

#	Article	IF	CITATIONS
19	Hepatitis E virus seroprevalence among schistosomiasis patients in Northeastern Brazil. Brazilian Journal of Infectious Diseases, 2016, 20, 262-266.	0.3	13
20	Enhanced liver fibrosis (ELF) score: Analytical performance and distribution range in a large cohort of blood donors. Clinica Chimica Acta, 2016, 461, 151-155.	0.5	6
21	Differential capacity of therapeutic drugs to induce Rods/Rings structures in vitro and in vivo and generation of anti-Rods/Rings autoantibodies. Clinical Immunology, 2016, 173, 149-156.	1.4	24
22	Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection. Brazilian Journal of Infectious Diseases, 2015, 19, 533-537.	0.3	13
23	Disease burden of chronic hepatitis C in Brazil. Brazilian Journal of Infectious Diseases, 2015, 19, 363-368.	0.3	15
24	Does hepatitis B virus coinfection have any impact on treatment outcome in hepatitis C patients on hemodialysis?. Annals of Hepatology, 2015, 14, 317-24.	0.6	1
25	Acute exacerbation of chronic hepatitis B virus infection in renal transplant patients. Brazilian Journal of Infectious Diseases, 2014, 18, 625-630.	0.3	10
26	Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial. Hepatology International, 2014, 8, 517-526.	1.9	6
27	Past and current hepatitis E virus infection in renal transplant patients. Journal of Medical Virology, 2014, 86, 948-953.	2.5	30
28	Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α. Immunologic Research, 2014, 60, 38-49.	1.3	24
29	First report and molecular characterization of hepatitis E virus infection in renal transplant recipients in Brazil. Journal of Medical Virology, 2013, 85, 615-619.	2.5	30
30	Longitudinal Study of a Human Drug-Induced Model of Autoantibody to Cytoplasmic Rods/Rings following HCV Therapy with Ribavirin and Interferon-α. PLoS ONE, 2012, 7, e45392.	1.1	53
31	Transcriptionâ€mediated amplification (TMA) for the assessment of viremia in hemodialysis patients with hepatitis C. Journal of Medical Virology, 2012, 84, 596-600.	2.5	7